Edwin Kingsley, MD
Hematology & Oncology · Las Vegas, NVNPI 1336156199
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 312 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NV, where the typical reported total is $9,657.
Across 312 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$1K
- Novartis$1K
- Beigene USA, Inc.$434
- E.r. Squibb & Sons, L.L.C.$373
- Johnson & Johnson$296
- Lilly USA, LLC$243
- plus $2K from 27 others
Across 1,005 payments — averaging $9136.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$6.3M
- Pfizer$1M
- Incyte Corporation$435K
- Seagen Inc.$366K
- Beone Medicines Ltd.$272K
- Sumitomo Pharma America, Inc.$148K
- plus $671K from 16 others
What the payments were for
- Food & beverage$5,44594%
- Education$3616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 137 | $1,308 |
| Novartis | 57 | $1,100 |
| Beigene USA, Inc. | 18 | $434 |
| E.r. Squibb & Sons, L.L.C. | 4 | $373 |
| Johnson & Johnson | 7 | $296 |
| Lilly USA, LLC | 2 | $243 |
| Seagen Inc. | 7 | $189 |
| Sirtex Medical Inc | 2 | $164 |
| Boston Scientific | 1 | $150 |
| Servier Pharmaceuticals LLC | 7 | $147 |
| Bristol Myers Squibb | 7 | $129 |
| Pfizer | 12 | $128 |
| Merck | 6 | $128 |
| Genentech USA, Inc. | 3 | $119 |
| Sanofi | 5 | $113 |
| Amgen | 6 | $112 |
| EMD Serono, Inc. | 4 | $76 |
| Beone Medicines USA, Inc. | 3 | $76 |
| Sobi, Inc | 3 | $62 |
| Exelixis Inc. | 2 | $55 |
| Astellas Pharma US Inc | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Apellis Pharmaceuticals, Inc. | 1 | $51 |
| Incyte Corporation | 2 | $42 |
| GSK | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Morphosys, US Inc. | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Forte Bio-pharma LLC | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$325
- ICEfx Cryoablation System$150
- SIR-Spheres Microspheres$146
- RYBREVANT$125
- CARVYKTI$125
How this compares
$5,805 in reported general payments places this provider in the 35th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 72 | $1,588,945 |
| Lenalidomide | 69 | $981,194 |
| BrukinsaZanubrutinib | 47 | $678,013 |
| VenclextaVenetoclax | 53 | $514,818 |
| TibsovoIvosidenib | 13 | $433,506 |
| TagrissoOsimertinib Mesylate | 24 | $431,835 |
| MekinistTrametinib Dimethyl Sulfoxide | 26 | $400,580 |
| RevlimidLenalidomide | 19 | $382,848 |
| TafinlarDabrafenib Mesylate | 26 | $368,951 |
| ErleadaApalutamide | 23 | $348,018 |
| CabometyxCabozantinib S-Malate | 11 | $279,485 |
| IbrancePalbociclib | 16 | $241,004 |
| XtandiEnzalutamide | 15 | $229,507 |
| BosulifBosutinib | 11 | $222,526 |
| NubeqaDarolutamide | 11 | $140,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $373 | $1,588,94572 claims |
| NovartisMekinist, Tafinlar | $1,100 | $769,53152 claims |
| Beigene USA, Inc.Brukinsa | $434 | $678,01347 claims |
| PfizerIbrance, Bosulif, Eliquis | $128 | $540,134127 claims |
| Johnson & JohnsonErleada, Xarelto | $296 | $438,081112 claims |
| Servier Pharmaceuticals LLCTibsovo | $147 | $433,50613 claims |
| AstraZenecaTagrisso | $16 | $431,83524 claims |
| Bristol Myers SquibbRevlimid | $129 | $382,84819 claims |
| Exelixis Inc.Cabometyx | $55 | $279,48511 claims |
| Astellas Pharma US IncXtandi | $53 | $229,50715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Nicholas VogelzangLas Vegas$397K
- Wolfram SamlowskiLas Vegas$235K
- Oscar GoodmanLas Vegas$211K
- Aaron GoodmanLas Vegas$134K
- Anuradha ThummalaLas Vegas$128K
- Ann WiermanLas Vegas$81K
- Heather AllenLas Vegas$78K
- Holavanahalli Keshava-PrasadLas Vegas$67K
- Edgardo FaylonaLas Vegas$53K
- Khawaja JahangirLas Vegas$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.